Biogen, Sage

Sage rejects Biogen's $469 million takeover offer
Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen. The company said Biogen's offer to buy all outstanding shares of Sage that it does not already own for $7.
Sage Rejects Biogen’s Unsolicited Offer, Will Seek Strategic Alternatives
Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million.
Sage rejects Biogen’s buyout offer, but says it's open to deals
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen Inc.
Sage Therapeutics Explores Alternatives, Rejects Biogen's Proposal, Stock Up
(RTTNews) - Sage Therapeutics, Inc. (SAGE) Monday announced that its Board of Directors has initiated a strategic review process aimed at maximizing shareholder value, involving a wide range of options, such as potential strategic transactions, business combinations, or the sale of the company.
Sage Rejects Biogen Bid, Launches Review of Alternatives
Sage Therapeutics has rejected a buyout bid from partner Biogen and launched a review of strategic alternatives. Sage on Monday said its board determined that Biogen's $7.22-a-share proposal significantly undervalues the biopharmaceutical company and isn't in the best interest of its shareholders.
Sage rejects Biogen's $469 million takeover offer, says offer undervalues company
Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve shareholders' best interests.
Sage Therapeutics rejects Biogen bid, starts strategic review
Sage Therapeutics rejected a takeover offer from Biogen and said it started a process to review its strategic alternatives. Sage rose 5.6%. Sage's board will look at

Eisai, Biogen

Biogen’s Hold Rating: Balancing Modest Gains and Strategic Uncertainty
BTIG analyst Thomas Shrader has maintained their neutral stance on BIIB stock, giving a Hold rating on January 23.Invest with Confidence: ...
Biogen CEO tells Governor Healey he’s concerned about ‘a lot more policy risk’ in D.C.
Chris Viehbacher spoke out about the uncertain policy environment for life sciences companies, though he didn't single ...
This Week in Chancery Court: Biogen, T-Mobile, Repsol SA
Biogen Inc. is fending off a lawsuit in the Delaware Chancery Court over its recent offer to buy out Sage Therapeutics, its ...
Wedbush Forecasts Biogen’s FY2024 Earnings (NASDAQ:BIIB)
Equities research analysts at Wedbush dropped their FY2024 EPS estimates for Biogen in a research report issued on Thursday, ...
FierceBiotech4d
Biogen research team hit by layoffs as company shifts resources to external opportunities
Biogen has been in the news recently after longtime partner Sage Therapeutics filed a lawsuit against the company after ...